No data to show
XNAS
SLRX
Market cap1mUSD
Jun 06, Last price
0.72USD
1D
-4.12%
1Q
-31.19%
Jan 2017
-100.00%
IPO
-100.00%
Name
Salarius Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
49.06%
Rev. gr., 5y
26.48%
Revenues
0k
Net income
-6m
CFO
-5m
L-64.77%
Earnings
Aug 07, 2025
Profile
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 5,734 | 10 | 22,982 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (5,734) | (10) | (22,982) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (233) | |||||||||
Tax Rate | ||||||||||
NOPAT | (5,734) | (10) | (22,749) | |||||||
Net income | (5,576) | (31,375) 146.96% | ||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 1,526 | 6,921 | 1,987 | |||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | 222 | 290 | ||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 352 | 1,408 | ||||||||
Net debt | (2,213) | (5,610) | (12,106) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (4,525) | (12,846) | (17,595) | |||||||
CAPEX | (3) | (1,500) | ||||||||
Cash from investing activities | (1,500) | |||||||||
Cash from financing activities | 1,060 | 6,640 | 1,987 | |||||||
FCF | (5,734) | (10) | (22,741) | |||||||
| Balance | ||||||||||
Cash | 2,435 | 5,900 | 12,106 | |||||||
Long term investments | ||||||||||
Excess cash | 2,435 | 5,900 | 12,106 | |||||||
Stockholders' equity | (81,923) | (76,347) | (63,805) | |||||||
Invested Capital | 84,009 | 81,924 | 74,190 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 962 | 3,265 | 2,125 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | (5,730) | (22,975) | ||||||||
EV/EBITDA | ||||||||||
Interest | 233 | |||||||||
Interest/NOPBT | ||||||||||